Severe eosinophilic asthma: therapeutic potential of Reslizumab

Severe eosinophilic asthma: therapeutic potential of Reslizumab

The review discusses the problems associated with the treatment of patients with severe resistant to therapy asthma: prevalence, socio-economic burden, impact on quality of life. The phenotype of bronchial asthma with eosinophilic inflammation, frequency of occurrence, clinical features, and modern...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical Council 2018-10 (15), p.70-75
1. Verfasser: Fassakhov, R. S.
Format: Artikel
Sprache:eng ; rus
Schlagworte:
eosinophilic inflammation
interleukin 5
reslisumab
severe bronchial asthma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The review discusses the problems associated with the treatment of patients with severe resistant to therapy asthma: prevalence, socio-economic burden, impact on quality of life. The phenotype of bronchial asthma with eosinophilic inflammation, frequency of occurrence, clinical features, and modern approaches to therapy are discussed in detail, including the use of a drug of monoclonal antibodies against interleukin 5-reslizumab.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2018-15-70-75